Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The antibodies specialist says its Vitamin D antibody sales helped drive revenue growth
Thursday 19 Oct 2017 Author: Lisa-Marie Janes

Antibodies developer Bioventix (BVXP:AIM) achieved better than expected sales for its financial year to 30 June, up 31% to £7.2m. The results were particularly boosted by its Vitamin D antibody vitD3.5H10 for deficiency testing.

Full year earnings per share also beat expectations by 7%, which was driven by higher sales, gross margins and a lower tax charge.

Shareholders are being rewarded with a 40p per share special dividend, alongside a 31p normal dividend. (LMJ)

‹ Previous2017-10-19Next ›